Community acquired bacterial pneumonia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 3, 2010, Pages 361-374

  Anevlavis, Stavros ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

CAP; Community acquired pneumonia; Pneumonia; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CETHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; DAPTOMYCIN; DOXYCYCLINE; DROTRECOGIN; ERYTHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TELITHROMYCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL PNEUMONIA; BLOOD CULTURE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LEGIONELLA PNEUMOPHILA; LENGTH OF STAY; LEUKOCYTE COUNT; LIVER TOXICITY; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MYCOPLASMA PNEUMONIAE; PNEUMOCYSTIS JIROVECI; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN BLOOD LEVEL; RESPIRATORY VIRUS; REVIEW; SCORING SYSTEM; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT FAILURE;

AGE FACTORS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 76449100180     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903508770     Document Type: Review

References (128)

1. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med 2009;30:179-188
2. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-1433
3. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008;14:727-733
4. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008;46:1513-1521
5. Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of communityacquired pneumonia patients admitted to the ward and the ICU. Chest 2008;133:610-617
6. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating communityacquired pneumonia. Clin Ther 1998;20:820-837
7. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000;109:378-385
8. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382
9. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250
10. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006;27:9-11
11. Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006;174:1249-1256 (Pubitemid 44924826)
12. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in communityacquired pneumonia. Clin Infect Dis 2008;47:375-384
13. Christ-CrainM, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93
14. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349-355
15. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128:2223-2229
16. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52:48-58
17. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10
18. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332:1077-1079
19. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006;32:469-472
20. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-452
21. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in communityacquired pneumonia. Am J Respir Crit Care Med 2007;176:913-920
22. Salluh JI, Bozza FA, Soares M, et al. Adrenal response in severe communityacquired pneumonia: impact on outcomes and disease severity. Chest 2008;134:947-954
23. Gotoh S, Nishimura N, Takahashi O, et al. Adrenal function in patients with community-acquired pneumonia. Eur Respir J 2008;31:1268-1273
24. Smith RP, Lipworth BJ, Cree IA, et al. Creactive protein. A clinical marker in community-acquired pneumonia. Chest 1995;108:1288-1291
25. Coelho L, Povoa P, Almeida E, et al. Usefulness of C-reactive protein in monitoring the severe communityacquired pneumonia clinical course. Crit Care 2007;11:R92
26. Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: what's new? Thorax 2004;59:364-366
27. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in communityacquired pneumonia. Am J Med 2008;121:219-225
28. Kruger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and provasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 2007;33:2069-2078
29. Masia M, Papassotiriou J, Morgenthaler NG, et al. Midregional pro- A-type natriuretic peptide and carboxyterminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007;53:2193-2201
30. Prat C, Lacoma A, Dominguez J, et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007;55:400-407
31. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006;10:R96
32. Schuetz P, Stolz D, Mueller B, et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 2008;8:22
33. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with communityacquired pneumonia. Chest 2004;126:1087-1092
34. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72
35. Flatauer FE, Chabalko JJ, Wolinsky E. Fiberoptic bronchoscopy in bacteriologic assessment of lower respiratory tract secretions. Importance of microscopic examination. JAMA 1980;244:2427-2429
36. Hahn HH, Beaty HN. Transtracheal aspiration in the evaluation of patients with pneumonia. Ann Intern Med 1970;72:183-187
37. Kalin M, Lindberg AA, Tunevall G. Etiological diagnosis of bacterial pneumonia by gram stain and quantitative culture of expectorates. Leukocytes or alveolar macrophages as indicators of sample representativity. Scand J Infect Dis 1983;15:153-160
38. Ries K, Levison ME, Kaye D. Transtracheal aspiration in pulmonary infection. Arch Intern Med 1974;133:453-458
39. Boerner DF, Zwadyk P. The value of the sputum gram's stain in communityacquired pneumonia. JAMA 1982;247:642-645
40. Anevlavis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum gram stain in pneumonia. J Infect 2009;59:83-89
41. Waterer GW, Wunderink RG. The influence of the severity of communityacquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82
42. Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with communityacquired pneumonia: a prospective observational study. Chest 2003;123:1142-1150
43. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-644
44. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A metaanalysis. JAMA 1996;275:134-141
45. Loens K, Beck T, Ursi D, et al. Development of real-time multiplex nucleic acid sequence-based amplification for detection of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. in respiratory specimens. J Clin Microbiol 2008;46:185-191
46. Kumar S, Wang L, Fan J, et al. Detection of 11 common viral and bacterial pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) or automated (electronic microarray) detection. J Clin Microbiol 2008;46:3063-3072
47. Nilsson AC, Bjorkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol 2008;8:93
48. Loens K, Beck T, Ursi D, et al. Evaluation of different nucleic acid amplification techniques for the detection of M. pneumoniae, C. pneumoniae and Legionella spp. in respiratory specimens from patients with community-acquired pneumonia. J Microbiol Methods 2008;73:257-262
49. Helbig JH, Uldum SA, Luck PC, Harrison TG. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol 2001;50:509-516
50. Roson B, Fernandez-Sabe N, Carratala J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004;38:222-226
51. Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001;119:243-249
52. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003;41:2810-2813
53. Benson RF, Tang PW, Fields BS. Evaluation of the Binax and Biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella. J Clin Microbiol 2000;38:2763-2765
54. Boulware DR, Daley CL, Merrifield C, et al. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect 2007;55:300-309
55. Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis 2003;36:64-69
56. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001;39:3495-3498
57. Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001;33:990-996
58. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton- Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-759
59. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-824
60. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillinresistant isolates. Clin Infect Dis 2003;37:1050-1058
61. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993;25:97-108
62. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-1444
63. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771
64. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired- MRSA pneumonia. Eur Respir J 2009;34:1148-1158
65. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-1132
66. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72
67. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16(Suppl 1):S31-S34
68. Geisel R, Schmitz FJ, Thomas L, et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999;43:846-848
69. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992
70. Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillinresistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004;126:314-315
71. Powers JH, Lin D, Ross D. FDA evaluation of antimicrobials: subgroup analysis. Chest 2005;127:2298-2299
72. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug- Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-1408
73. Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J 2008;31:1068-1076
74. Shefet D, Robenshtock E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2005;18:CD004418
75. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-1093
76. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-237
77. Campbell GD Jr, Silberman R. Drugresistant Streptococcus pneumoniae. Clin Infect Dis 1998;26:1188-1195
78. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997;24:1052-1059
79. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-1297
80. Vila-Corcoles A, Bejarano-Romero F, Salsench E, et al. Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia. BMC Infect Dis 2009;9:36
81. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis 2004;39(Suppl 3):S142-S150
82. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J Infect 2004;48:56-65
83. Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007;51:4382-4389
84. Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother 2004;54(Suppl 1):i23-i29
85. Pottumarthy S, Fritsche TR, Sader HS, et al. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. Int J Antimicrob Agents 2005;25:282-289
86. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003;36:963-970
87. Bradford PA, Petersen PJ, Tuckman M, Jones CH. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Clin Microbiol Infect 2008;14:882-886
88. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-338
89. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
90. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008;46:1142-1151
91. File TM Jr. The development of pharmacokinetically enhanced amoxicillin/ clavulanate for the management of respiratory tract infections in adults. Int J Antimicrob Agents 2007;30(Suppl 2):S131-S134
92. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 1990;323:1444-1450 (Pubitemid 20384952)
93. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990;323:1451-1457
94. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124
95. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005;33:952-961
96. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444
97. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10-21
98. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a betalactam- based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395
99. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-1842
100. Harbarth S, Garbino J, Pugin J, et al. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005;24:688-690
101. Aspa J, Rajas O, Rodriguez de CF, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006;27:1010-1019
102. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084
103. Marrie TJ, Wu L. Factors influencing inhospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005;127:1260-1270
104. Benenson R, Magalski A, Cavanaugh S, Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med 1999;6:1243-1248
105. Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008;149:29-32
106. Cheng AC, Buising KL. Delayed administration of antibiotics and mortality in patients with community-acquired pneumonia. Ann Emerg Med 2009;53:618-624
107. Yu KT, Wyer PC. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia. Ann Emerg Med 2008;51:651-62, 662
108. Baum SG, Kaltsas A. Guideline tyranny: primum non nocere. Clin Infect Dis 2008;46:1879-1880
109. Barlow G, Nathwani D, Myers E, et al. Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia. J Antimicrob Chemother 2008;61:442-451
110. Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008;168:351-356
111. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with communityacquired pneumonia. Arch Intern Med 1995;155:1273-1276
112. Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a metaanalysis. Drugs 2008;68:2469-2481
113. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a metaanalysis. Drugs 2008;68:1841-1854
114. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007;120:783-790
115. Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-508
116. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-965
117. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-160
118. Menendez R, Torres A, Rodriguez de CF, et al. Reaching stability in communityacquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-1790
119. Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988;93:318-324
120. Sanyal S, Smith PR, Saha AC, et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-348
121. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-1457
122. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993;147:38-44
123. Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990;97:576-582
124. Feinsilver SH, Fein AM, Niederman MS, et al. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 1990;98:1322-1326
125. Kuru T, Lynch JP III. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999;20:623-651
126. Menendez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757-762
127. Kaye KS, Harris AD, McDonald JR, et al. Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistance. Infect Control Hosp Epidemiol 2008;29:137-142
128. Garau J, Baquero F, Perez-Trallero E, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008;14:322-329